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ABSTRACT: Background. Controversy surrounds the appropriate ther-
apy for T1 glottic cancer. Both transoral endolaryngeal resection and
radiation offer excellent local control and voice quality; some lesions are
best addressed with resection and others with radiation.
Methods. The American College of Radiology (ACR) Appropriateness Cri-
teria are evidence-based guidelines for specific clinical conditions that
are reviewed by a multidisciplinary expert panel. The guideline develop-
ment includes an analysis of current literature from peer reviewed jour-
nals and the well-established “modified Delphi” consensus methodology
to rate the appropriateness of treatment. Where evidence is not defini-
tive, expert opinion informed recommendations.
Results. The ACR Expert Panel on Radiation Oncology – Head and Neck
Cancer developed consensus recommendations for treatment of T1 glot-
tic cancer. Treatment planning is complex and decisions nuanced.
Conclusion. Best treatment for a particular cancer cannot be defined
without consideration of the lesion’s location, extent, depth of invasion,
and quality of surgical exposure during direct laryngoscopy. VC 2013
American College of Radiology. Head & Neck VC 2013 Wiley Periodicals,
Inc. Head Neck 36: 3–8, 2014
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INTRODUCTION
Summary of literature review
Most laryngeal cancers arise in the glottis, which com-
prises, for purposes of clinical staging, the superior and
inferior surfaces of the true vocal cords (including the
anterior and posterior commissures). The glottis occupies
a horizontal plane 1 cm in thickness, extending inferiorly
from the lateral margin of the ventricle. Stage I T1N0
cancers are limited to the vocal cords and commissures,
with normal cord mobility. T1a lesions are limited to a
single cord, whereas disease that involves both cords is
stage T1b. A cancer with impairment in cord mobility
and/or extension to the supraglottis or subglottis is stage
II T2N0.1 Three-fourths of patients with laryngeal cancer
in North America present with stage I or II disease.2,3
Treatment of stage I glottic cancer is highly successful
and larynx preservation is usually achieved. Neither total
laryngectomy nor chemoradiation are indicated in the ini-
tial management of T1 glottic cancer, nor is treatment of
the neck.4
As single modalities, with intent to preserve the larynx,
both radiation and resection afford excellent locoregional
control and survival. The small number of treatment fail-
ures (through either initial approach), and local variations
in treatment preferences on the part of physicians, sur-
geons, and patients have frustrated efforts to perform
randomized trials comparing the modalities. Review of
the relevant literature reveals no properly designed and
reported randomized trials comparing surgical with radio-
therapeutic management of stage I glottic cancer.5 Thor-
ough recent meta-analyses have been performed.6,7 No
difference in survivorship could be demonstrated,
although there was better larynx preservation in patients
treated with initial resection. A recent review has consid-
ered “levels of evidence” supporting treatment options for
glottic cancer.8 Use of chemotherapy alone to treat stage
I glottic cancer should be considered investigational.9
Radiation treatment
Surgical treatment of early glottic cancers with total
laryngectomy or open partial laryngectomy was
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historically associated with loss of normal voice or sub-
stantial decline in its quality. Radiation treatment has
been associated with local control rates from 80% to
95%,10–14 and shorter overall treatment times seem to
yield superior results.14,15 A prospective randomized
study comparing 2 Gy fractions with 2.25 Gy fractions
(with 60 Gy in 30 fractions vs 56.25 Gy in 25 fractions
for lesions involving less than two-thirds of the vocal
cord and, for larger lesions, 66 Gy in 33 fractions vs 63
Gy in 28 fractions) showed a significant advantage in
local control rate for the shorter treatment time. Five-year
local control rate was 77% for the 2 Gy arm and 92% for
the 2.25 Gy arm (p 5 .004) with no significant difference
in survival, acute mucosal reaction, skin reaction, or late
effects.16 Recent results from a single-institution series,
including some 325 patients with stage I glottic cancer
treated with opposed lateral fields, demonstrated 10-year
local control rates of 93% for T1a and 91% for T1b. Ulti-
mate local control rates (including successful salvage
after local recurrence) were 98% and 95% for T1a and
T1b lesions, respectively.17
Many of the reported radiotherapy outcomes include
patients treated predominantly with cobalt-60 units or 2
to 4 MV x-rays.18–21 Several authors showed inferior
local control with cobalt-60,15,18 unlike the majority of
published results17,22,23; some have also reported inferior
results with 6 MV photons.24 The effect of treatment
energy is difficult to isolate because of concomitant tech-
nologic advances that transpired during the shift from
cobalt to linear-accelerator delivered therapy. Concerns
regarding adequate dose delivery with higher energy 6
MV photons existed previously, but they have largely
been assuaged.25,26
Radiation has typically been delivered with opposing
lateral low-energy photon fields with wedges; other
approaches described include oblique fields,27 a 3-field
approach,17,20 a single appositional electron field,18 and a
single lateral field.22 Regardless of the field arrangement
chosen, elective treatment of the neck is not warranted.28
Field size is generally 5 cm 3 5 cm. Nonrandomized
data concerning field size have been contradictory. Some
series suggest inferior local control when larger field sizes
are used (although many included patients with T2 dis-
ease, perhaps demanding a larger field and expected to
manifest inferior control).22,29 Others report better local
control with a field size >5 cm 3 5 cm,11,12,30 or no
impact of field size on local control,10,15,18,23 or excellent
outcomes with smaller field sizes.25 In a randomized con-
trolled trial for patients with T1 disease, subjects were
treated with either a 5 cm 3 5 cm or 6 cm 3 6 cm field.
Local control was excellent in both arms, with no differ-
ence between the smaller and larger field sizes.13
Shorter overall treatment times have seemed to yield
superior results.14,15 Prolongation of total treatment time
has been shown to negatively impact local control.23,31,32
Conversely, in 1 series, split-course therapy with a
planned 3-week break did not negatively impact local
control outcomes but did result in worsening toxicities.19
Intensity-modulated radiation therapy (IMRT) has been
considered feasible in order to diminish dose to the
carotid arteries,33,34 although its benefit has not been clin-
ically demonstrated. A dosimetric study comparing
opposed lateral fields, 3D conformal with either 2 oblique
and 1 anterior field or a lateral and anterior field, and 7-
field IMRT showed similar target volume coverage for all
techniques but reduced dose to the carotid arteries with
3D conformal planning and additional reductions with
IMRT. This dosimetric sparing of the carotid arteries is
balanced by concerns because of increased dose heteroge-
neity across the larynx as well as an uncertain impact of
target motion during treatment delivery.33 Another dosi-
metric study compared opposed lateral treatment plans
with IMRT plans created using 3 fields. Again, significant
reduction in dose to carotid arteries was possible. These
investigators also reported successful delivery of treat-
ment using IMRT in an 11-patient pilot series. A prospec-
tive series is planned.34
Photodynamic therapy has demonstrated encouraging
results for T1 glottic cancer as initial treatment and in a
salvage setting; however, it has not been widely
adopted.35
Surgical treatment
After Billroth to a great degree initiated modern surgi-
cal treatment of laryngeal cancer with the first reported
total laryngectomy and the first vertical hemilaryngec-
tomy,36 procedures to treat glottic cancer with operations
increased in popularity, scope, and ambition. Even for T1
glottic cancers, there have been many modifications and
extensions of open partial laryngectomy, because the
locations of different cancers create varying technical
challenges for the surgeon. In practice, tumors of the
membranous vocal fold (cord), those with extensions to
the anterior commissure, those actually involving the
commissure, those involving the arytenoid, and those
involving both cords must be managed differently.37
The nature of the resections, their functional conse-
quences, and their oncologic results depend strongly on
the extent of glottic involvement with respect to both sur-
face extent and to depth of invasion. Because surgical
treatment should be tailored to a particular tumor, the
management is individualized. However, principles
include preoperative laryngoscopy (which may include
videolaryngostroboscopy), assurance of adequate intraop-
erative exposure, and resection to clear margins, if feasi-
ble. Collaboration with experienced pathologists is of
benefit.38 Transoral excision of T1 glottic cancer lacks
the morbidity of open procedures, and it is usually
accomplished expeditiously, with hospital stays under
3 days. For T1 lesions, the 5-year larynx-preservation
rate (in 2 series of more than 400 patients each) exceeds
97%, although “salvage” treatment may be required to
achieve the reported locoregional control of 96%
to 99%.38,39
Most open laryngectomies produce a decline in voice
quality. Voice quality depends most strongly on the
amount and depth of cord resection, and formal criteria to
describe the cordectomy performed have been elabo-
rated.40,41 For most midcord T1a cancers, the overall
voice quality after resection or radiation is similar,
although the specific voice profiles seem different.42 A
CO2 laser is typically used, but other cutting tools may
be employed. Functional and oncologic results for super-
ficial disease of a single cord are excellent. Surgical
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tumor control declines for tumors truly involving the
anterior commissure, with a substantial increase in recur-
rence frequency, which even in experienced hands43,44
may exceed 20%.
Quality of voice and life
Voice quality after treatment for glottic cancer with
cordectomy and with radiation has been assessed both
subjectively and objectively. Because patients with T1
glottic cancer usually have an abnormal voice, it com-
monly improves after treatment. Although patient satisfac-
tion and subjective evaluation of voice quality are often
high after either surgery or radiation, more formal studies
demonstrate changes associated with tumor size and
extent of resection.45–47 The Voice Handicap Index of
pooled results from small series shows no significant dif-
ference between patients treated with laser excision and
radiation. Maximum phonation time seems to favor
patients treated with radiation. With respect to airflow,
fundamental frequency, microperturbation in frequency,
and microperturbation in amplitude, no significant differ-
ences were demonstrated.6,48 Prospective studies of voice
quality are justified.48 In the treated population, smoking
seems to affect voice quality.49,50 There is no significant
difference in the University of Washington Quality-of-
Life instrument or the Performance Status Scale for Head
and Neck Cancer Patients for patients with T1 glottic can-
cer treated with endoscopic resection or radiation51 (Vari-
ant 1, Variant 2, Variant 3, and Variant 4).
Treatment of recurrence
Surgical salvage of patients with recurrence after defin-
itive radiation should be attempted. Success seems largely
related to the extent of tumor at the time of resection.
Total laryngectomy is often required, but smaller proce-
dures (ranging from laser excision through supracricoid
laryngectomy) may be appropriate and successful.52–55
Both radiation and resection may be used to salvage
patients with recurrence after prior resection.56 Patients
initially treated with radiation have a far higher risk of
eventual laryngectomy than those whose cancer was first
treated with transoral laser excision.57 Analysis of patients
with less deeply invasive tumors (those with normal or
diminished mucosal wave, as opposed to absent wave, or
videolaryngostroboscopy) still suggests a higher risk for
larynx loss in patients initially addressed with radiation58
(Variant 5).
VARIANT 1. A 57-year-old man has squamous cancer superficially involving the mid-third of the left true vocal cord. Cord motion is normal, and videostro-
boscopy shows an intact mucosal wave. The lesion can be readily defined on office examination. He is edentulous, can open his mouth well, and
ceased smoking 5 years ago. The cancer can be seen in its entirety with direct laryngoscopy with the patient under anesthesia.
Treatment Rating Comments
Total laryngectomy 1
Open partial laryngectomy 3
Transoral endolaryngeal resection 9
External beam radiation in 2 Gy fractions 3
External beam radiation in 2.25 Gy fractions 7
Concurrent chemoradiation with cisplatin 1
Rating scale: 1, 2, and 3 are usually not appropriate; 4, 5, and 6 may be appropriate; and 7, 8, and 9 are usually appropriate.
This is a T1 glottic cancer. All of the methods described should afford excellent control of the cancer, albeit with dramatic differences in subsequent quality of life. Neither total laryngectomy nor
concurrent chemoradiation is appropriate for treatment of this lesion. Open partial laryngectomy has more side effects than transoral laryngeal surgery (including a longer hospital stay and need for
a temporary tracheotomy). External beam radiation therapy in 2.25 Gy fractions is superior to treatment with 2 Gy fractionations. Both radiation treatment and surgery should confer high quality of
life and voice in treating cancers such as this.
VARIANT 2. A 57-year-old man has squamous cancer superficially involving the mid-third of the left true vocal cord. Cord motion is normal. He is hoarse,
and the mucosal wave is dampened on videostroboscopic examination. The lesion can be defined on office examination. He is edentulous, ceased




Open partial laryngectomy 7
Transoral endolaryngeal resection 4 Transoral endolaryngeal resection should only be performed in this
scenario by an experienced surgeon, realizing the potential need to
convert to an open procedure.
External beam radiation in 2 Gy fractions 3
External beam radiation in 2.25 Gy fractions 9
Rating scale: 1, 2, and 3 are usually not appropriate; 4, 5, and 6 may be appropriate; and 7, 8, and 9 are usually appropriate.
Despite the difficulty of exposing this cancer under anesthesia, oncologic control of this tumor should not be more difficult to achieve than in patients whose lesion is more readily defined. Total lar-
yngectomy is not justified. Transoral laryngeal excision should not be performed if the lesion cannot be seen in its entirety during examination under anesthesia. Open partial laryngectomy may be
performed with excellent margins, despite inability to expose the tumor fully through line of sight, because angled telescopes may be used to examine the larynx. Quality of voice with open partial
laryngectomy is likely to be inferior to that achieved through radiation treatment of this cancer. External beam radiation therapy in 2.25 Gy fractions is superior to treatment with 2 Gy fractions.
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VARIANT 3. A 65-year-old man has squamous cancer densely involving the anterior third of both vocal cords. Cord motion is normal, as is videostrobo-
scopy. The lesion can be defined on office examination. Imaging shows no involvement of the thyroid cartilage. He is edentulous, ceased smoking 5
years ago, and takes no medicines. The cancer can be exposed in its entirety with direct laryngoscopy with the patient under anesthesia.
Treatment Rating Comments
Total laryngectomy 1
Open partial laryngectomy 7
Transoral endolaryngeal resection 5 Transoral endolaryngeal resection should only be performed in this
scenario by an experienced surgeon, realizing the potential need to
convert to an open procedure.
External beam radiation in 2.25 Gy fractions 9
Concurrent chemoradiation with cisplatin 1
Rating scale: 1, 2, and 3 are usually not appropriate; 4, 5, and 6 may be appropriate; 7, 8, and 9 are usually appropriate.
Neither total laryngectomy nor concurrent chemoradiation is justified for this patient with T1b glottic cancer. Transoral laser excision may entail a decline in local control because of the anterior
commissure involvement. Open partial laryngectomy (including perhaps a supracricoid partial laryngectomy) should confer adequate tumor control, although voice quality will suffer and morbidity is
substantial. External beam radiation should not involve a compromise in tumor control, although voice quality is likely to be inferior to that after treatment of a superficial T1a lesion.
VARIANT 4. A 65-year-old man has undergone 3 prior vocal cord stripping procedures to address carcinoma in situ of the left true vocal cord. Cord motion
is normal. The lesion cannot be readily defined on office examination, but he brings video documentation of the most recent treatment. He is edentu-
lous, ceased smoking 5 years ago, and takes no medicines. With examination under anesthesia and microdirect laryngoscopy the cord shows evidence
of prior manipulation, but no lesion can be seen. Biopsy again shows carcinoma in situ.
Treatment Rating Comments
Photodynamic therapy 8 Need for sun exposure is a contraindication to this treatment option.
Patients should be carefully staged surgically with particular atten-
tion to defining the depth of the lesion.
Open partial laryngectomy 2
Transoral endolaryngeal resection 4
External beam radiation therapy 8
Rating scale: 1, 2, and 3 are usually not appropriate; 4, 5, and 6 may be appropriate; 7, 8, and 9 are usually appropriate.
Open partial laryngectomy with cordectomy will entail hospitalization and result in voice decline. It is too morbid an approach for carcinoma in situ of the cord. Photodynamic therapy can be accom-
plished without hospitalization, can be performed repeatedly, and preserves voice quality. It may prove disruptive for individuals with an outdoor occupation or lifestyle and is not available every-
where. Transoral laryngeal surgery should not be undertaken if the site of disease cannot be defined preoperatively. Radiation therapy should confer excellent results in addressing this problem (for
control of carcinoma in situ and with respect to voice quality).
VARIANT 5. A 68-year-old man has recurrent squamous cancer superficially involving the mid-third of the left true vocal cord after radiation 1 year ago.
Cord motion is normal. He is hoarse. The lesion can be readily defined on office examination. He is edentulous, can open his mouth well, ceased smok-
ing 5 years ago, and takes no medicines. The cancer can be seen in its entirety with direct laryngoscopy with the patient under anesthesia.
Treatment Rating Comments
Systemic chemotherapy 1
Reirradiation to recurrent tumor volume with limited margin
(0.5–2 cm) and concurrent chemotherapy
1
Reirradiation to recurrent tumor volume and elective coverage
of neck levels II and III with concurrent chemotherapy
2
Total laryngectomy 3
Open partial laryngectomy 7
Transoral endolaryngeal resection 8
Photodynamic therapy 7 Need for sun exposure is a contraindication to this
treatment option. Patients should be carefully
staged surgically with particular attention to
defining the depth of the lesion.
Rating scale: 1, 2, and 3 are usually not appropriate; 4, 5, and 6 may be appropriate; 7, 8, and 9 are usually appropriate.
Clinically, this rT1 glottic cancer is treatable with curative intent. Use of systemic chemotherapy, which is palliative, is not appropriate in this setting. The same applies to reirradiation, which should
not be used if resection can be performed with acceptable morbidity and reasonable expectation of tumor control. The true extent of tumor is difficult to define in this setting, since the cancer is
often submucosal. It may be far more extensive than examination suggests. Hence, whereas efforts at larynx preservation are appropriate (and frequently successful with either open or endoscopic
techniques), patients should be prepared for total laryngectomy. Technical demands of the procedures exceed those performed in patients who have not received radiation treatment. Photodynamic
therapy may cure patients who develop superficial recurrences after radiation fails.
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Costs of care
Several analyses of the monetary costs of care for a
patient with T1 glottic cancer have been performed. Vari-
ous degrees of sophistication have been used. A recent
evaluation comparing transoral laser excision with radia-
tion for T1 glottic cancer indicates that resection is the
less costly approach, principally because the costs to con-
trol a recurrence after surgery are less than those needed
to salvage a postradiation recurrence.7 Assumptions sur-
rounding the nature and extent of the treatments for recur-
rence strongly affect such calculations. “Hidden costs” of
care at a major center demonstrated substantial differen-
ces in number of treatments, median necessary travel dis-
tances, total median travel time, and median number of
work hours missed—indicating that other factors besides
oncologic control and voice quality warrant consideration
in management.51
Patients living far from a radiation facility and those
who face difficulty with transportation or mobility are
often far more appropriate candidates for resection than
for radiation treatment, because the episode of care is
considerably shorter, with equivalent oncologic results.
Photodynamic therapy has demonstrated encouraging
results for T1 glottic cancer as initial treatment and in a
salvage setting; however, it has not been widely adopted.
Summary
Surgical treatment: The panel recommends transoral
endolaryngeal resection for patients with T1a disease visi-
ble in its entirety on direct laryngoscopy and an intact
mucosal wave. This offers excellent control outcomes and
a favorable morbidity profile.
Radiation treatment: Radiation therapy offers excellent
local control and is the preferred first-line therapy in
patients with disease not readily amenable to transoral
laryngeal resection. Open partial laryngectomy is a viable
alternative, although the vocal quality may be better with
radiation therapy. Randomized data support the use of
2.25 Gy fractions as opposed to 2.0 Gy.
Recurrent disease: Most patients with disease recurrence
remain candidates for additional definitive treatment, with
best therapy at recurrence dependent on the initial treat-
ment strategy. Although larynx preservation remains
achievable, patients should be counseled regarding the
potential requirement for total laryngectomy.
Costs of care: Thorough costs of care analyses are chal-
lenging, due in large part to the difficulty of accurately
assessing the hidden costs of initial treatment as well as
potential subsequent costs of caring for recurrences.
Treatment of choice for many patients will ultimately
depend on patient-specific rather than disease-specific
factors, including proximity to treatment centers and pro-
fessional obligations.
For additional information on ACR Appropriateness
CriteriaVR , refer to www.acr.org/ac.
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